

Drug Discovery Toxicology Specialty Section

ANNUAL REPORT: 2021–2022

May 1, 2021 to April 30, 2022

I. Officers/Committees

<u>Officer</u>	<u>2021–2022</u>	<u>2022–2023</u>
President:	Marie Lemper	Brandon D. Jeffy
President-Elect/Vice President:	Brandon Jeffy	Jonathan M. Maher
	Jonathan M. Maher	Satoko Kiyota
Secretary/ Treasurer:	Satoko Kiyota	Marianna Stamou
Past President:	Zoe Zhong	Marie Lemper
Councilors:	Connie Wu	Saurabh G. Vispute
	Saurabh Vispute	Lauren Lewis
Postdoctoral Representative:	Souvarish Sarkar	Souvarish Sarkar
Graduate Student Representative:	Ray Hau	Raymond Kin Hau

Committees, if applicable:

II. 2021 Membership total: 318

III. Key Outcomes in 2021–2022:

- 2022 SOT Annual Meeting Activities
 - DDTSS was the primary endorser for one symposium and one CE course, and the secondary endorser for two symposium sessions.
 - DDTSS hosted a reception at the 2022 SOT annual meeting in San Diego. There was a brief business meeting which included an award ceremony for outgoing officers and a session that featured presentations from winners of recent competitions (the “Paper of the Year” competition and poster competitions for graduates and postdoc researchers) of 2020 and 2021.
 - See additional information under *A. 2022 SOT Annual Meeting Activities* and *B. 2022 Awards Information* under *IV. Activities*
- DDTSS hosted webinars in Q4, 2021 and Q2, 2022. See detailed information in *C. Other Educational Activities Conducted* under *IV. Activities*.
- The DDTSS annual newsletter for 2021 was circulated to the membership in October 2021.

IV. Activities

- SOT Annual Meeting Activities (e.g., courses, scientific sessions, receptions):
 - Courses and scientific sessions

Type	Title	Date and Time	
Symposium	Precise Modulation of the Immune System by Therapeutics: Lessons Learned	March 29, 2022 1PM – 2:30PM PT	Primary endorser
CE course	AM06: Safety Evaluation Strategies in Drug Discovery: From Target Assessment to Identification of Drug Candidates	March 27, 2022 8:15AM – 12:00PM PT	Primary endorser

Symposium	It Takes Guts: Exploring New Models and Modalities for Gastrointestinal Toxicity	March 28, 2022 1:45PM – 4:30PM PT	Secondary endorser
Symposium	How to Maximize the Value of Electronic Data via Analytics and Exchange to Create Knowledge: Case Studies across the Pharmaceutical Industry and Regulatory Sectors	March 28, 2022 9:15AM – 12:00PM PT	Secondary endorser

- Reception: DDTSS held a reception at the 2022 SOT Annual Meeting in San Diego. The program involved announcing the winners for the Drug Discovery Toxicology Paper of the Year Award, and the 2021 DDTSS Student and Postdoctoral Fellow Poster Competitions. Outgoing and incoming officers and upcoming webinars were announced, and participants had the opportunity to reconnect and network with colleagues.
- Mentoring luncheon: DDTSS held a mentoring luncheon for students and postdocs at the 2022 SOT Meeting in San Diego on March 28th at noon Pacific Time. Attendees had the opportunities to discuss with DDTSS Officers and get their questions answered regarding careers in pharmaceutical drug discovery toxicology
- 2022 Awards Information:
 - 1st place Graduate Student Poster Competition: Ray Hau
 - 2nd place Graduate Student Poster Competition: Rulaiha Taylor
 - 3rd place Graduate Student Poster Competition: Lydia Zhang and Shreyas Gaikwad
 - 1st place Postdoc Poster Competition: Dr. Souvarish Sarkar
 - 2nd place Postdoc Poster Competition: Dr. Dinesh Babu
 - 3rd place Postdoc Poster Competition: Dr Muthanna Sultan and Dr. Kumaravel Mohankumar
 - Paper of the year award: Ruth Roberts, Richard A Campbell, Phumzile Sikakana, Claire Sadler, Mark Osier, Yili Xu, Joy Y Feng, Michael Mitchell, Roman Sakowicz, Anne Chester, Eric Paoli, Jianhong Wang, Leigh Ann Burns-Naas. TOXICOLOGICAL SCIENCES, 183(1), 2021, 105-116; Species-Specific Urothelial Toxicity With an Anti-HIV Nucleoside Site Integrase Inhibitor (NCINI) Is Related to Unusual pH-Dependent Physicochemical Changes
- Other Educational Activities Conducted (e.g., webinars, in-person meetings):
The following webinars were hosted by the DDTSS in 2021-2022:
DDTSS Webinar: Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia
Date and Time: Wednesday, October 27 at 1 - 2pm ET
Speaker: Christine Karbowski, PhD

DDTSS webinar: Understanding Neurotoxicity Assays and Interspecies Differences to Address Attrition in Drug Discovery
Date and Time: Thursday, April 15th at 2pm ET

Speakers: Thomas Hartung, MD, PhD, Professor at Johns Hopkins Bloomberg School of Public Health, Baltimore, MD and Remco Westerink, PhD, Associate Professor at the Utrecht University in the Netherlands

- Communication Activities:
 - Newsletter publication frequency: once per year in Q4
 - New or significant announcements/blogs: via e-mail to membership
 - Highlights of website enhancements: The DDTSS website has been maintained and updated as needed
- Mentoring Activities: See under *IV. Activities*.

V. Feedback and Ideas:

- In what ways is your group fostering and maintaining an inclusive environment? Please give examples of any current practices used to support inclusion in processes such as 1) leadership selection and promotion, 2) award descriptions and selection, and 3) endorsement of proposals for the annual meetings.

DDTSS has focused on quality and strength of scientific discussions when reviewing applications for awards and session proposals but not affiliations or demographic aspects (race, ethnicity) based on applicant names and countries. All SOT/DDTSS members in good membership standing are eligible and encouraged to self-nominate for DDTSS leadership positions.

- How might SOT better support your group's activities (perhaps something the Society should be doing that we currently do not do, or do not do effectively, that would be of importance/benefit to the members of your component group?):
Note: If funding is listed, please provide detail on the membership need that the funding would support.

N/A

- What is one thing that the Society is currently doing that impacts your component group that should be changed (e.g., stopped, modified, etc.)?

N/A

- What changes do your component group anticipate making in the way in which it operates in the coming year?

N/A